Loading live market data…

AbbVie Inc.

NYSE:ABBV

$247.17 USD

$2.39 (0.98%)

Volume
1.25M
Average Volume
7.21M
Market Capitalization
$436.7B
P/E Ratio
121.21
Dividend Yield
2.76%
Price Target
$275.00
Year High
$261.64
Year Low
$184.63
Day High
Day Low
Payout Ratio
$3.25
Current Ratio
$0.80

Industry, Sector & symbol

Stock Exchange NYSE
CEO Robert A. Michael
Industry Drug Manufacturers - General
Sector Healthcare
Current Symbol ABBV
CUSIP 00287Y109
CIK 0001551152
Web https://www.abbvie.com
Phone 847 932 7900
Currency USD
Employees 57000
Country US

Liquidity

Debt-to-Equity Ratio 2.65
Payout Ratio 3.25
Current Ratio 0.80
Quick Ratio 0.68
Cash Ratio 0.22

Sales & Book Value

Annual Sales $61.16B
Price / Sales 6.95
Cash Flow 11.76
Price / Cash Flow 20.93
Price / Book 15.95

Price Target and Rating

Average Stock Price Forecast $275.00
High Stock Price Forecast $300.00
Low Stock Price Forecast $223.00
Forecast Upside/Downside -10.12%
Consensus Rating Sell
Rating Score(0-5) 2
Research Coverage 41 Analysts

Profitability

EPS (Most Recent Fiscal Year) $2.37
Trailing P/E Ratio 121.21
PEG Ratio -9.19
P/E Growth -9.19
Net Income $4.23B
Net Margin 5.79%
Pretax Margin 9.51%
Return on Equity 68.01%
Return on Assets 2.67%

Financials Score

AltmanZ Score 2.83
Piotroski Score 7.00
Working Capital -8.57B
Total Assets 136.46B
Ebit 8.88B
Market Cap 438.16B
Total Liabilities 108.96B

Poll Results

About AbbVie Inc. (NYSE:ABBV) Stock

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals wi ... th chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

2026-07-15 10:05:27

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap

2026-07-15 07:45:54

Both AbbVie (NYSE:ABBV | ABBV Price Prediction) and Baxter International (NYSE:BAX) flashed the same technical signal this month: a golden cross, where the 50-day moving average pushed above the 200-day.

Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?

2026-07-14 10:30:22

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Which High-Yield ETF Is a Better Buy in 2026: Vanguard VYM vs iShares HDV?

2026-07-14 09:04:05

VYM offers broader diversification with lower costs, while HDV is a more concentrated ETF with a heavy weightage on defensive stocks.

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

2026-07-14 08:05:00

SkinMedica ® launches Regenerative Science Advisory Board to shape future innovation Expands its state-of-the-art research and development (R&D) facility to support the next generation of science-led innovation Debuts flagship retail experiences designed to support practice and patients' needs IRVINE, Calif., July 14, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, is proud to announce SkinMedica's expanded commitment to regenerative science, advancing investments that will support innovation, research, clinical insight, and patient experience.

Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb

2026-07-14 05:00:00

Voluntary pricing deals reduce uncertainty for major drugmakers. Drug pricing pressure won't affect every pharmaceutical company equally.

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

2026-07-13 17:06:04

Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon lose patent protection.

3 Dividend Stocks Built for Long-Term Buy-and-Hold Investors

2026-07-13 12:15:00

You need to look beyond the tech sector to find great dividend stocks for the long term.

Frequently Asked Questions

What is the current AbbVie Inc. (ABBV) stock price?

AbbVie Inc.(NYSE:ABBV) stock price is $247.17 in the last trading session. During the trading session, ABBV stock reached the peak price of $261.64 while $184.63 was the lowest point it dropped to. The percentage change in ABBV stock occurred in the recent session was 0.98% while the dollar amount for the price change in ABBV stock was $2.39.

ABBV's industry and sector of operation?

The NYSE listed ABBV is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of ABBV?

Nicholas J. Donoghoe | Executive Vice President and Chief Business & Strategy Officer
Elizabeth Shea | Senior Vice President of Investor Relations
Perry C. Siatis | Executive Vice President, General Counsel & Secretary
Wulff-Erik von Borcke | Senior Vice President & President of Oncology
Linda Ray | Senior VP & Chief Information Officer

How many employees does ABBV have?

Number of ABBV employees currently stands at 57000. ABBV operates from 1 North Waukegan Road, North Chicago, IL 60064-6400, US.

Link for ABBV official website?

Official Website of ABBV is: https://www.abbvie.com

How do I contact ABBV?

ABBV could be contacted at phone #847 932 7900 and can also be accessed through its website. ABBV operates from 1 North Waukegan Road, North Chicago, IL 60064-6400, US.

How many shares of ABBV are traded daily?

The average number of ABBV shares traded daily for last 3 months was 7.21M.

What is the market cap of ABBV currently?

The market value of ABBV currently stands at $436.7B with its latest stock price at $247.17